| Assessment Status | Rapid Review Complete |
| HTA ID | 23076 |
| Drug | Netarsudil-latanoprost |
| Brand | Roclanda® |
| Indication | Netarsudil-latanoprost is indicated for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient intraocular pressure reduction. |
| Assessment Process | |
| Rapid review commissioned | 20/12/2023 |
| Rapid review completed | 22/02/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that netarsudil-latanoprost be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
